News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Time to Buy Arena Pharmaceuticals, Inc. (ARNA) is Now



7/16/2012 7:06:55 AM

One of the benefits for investors who focus in specific sectors is that new opportunities can come from research. While researching Theravance (THRX) and Valeant (VRX) over the last few quarters, Arena Pharmaceuticals (ARNA) came up recently. A number of readers bought Arena when shares traded below $6. This leaves investors noticing shares at the current price paying two-fold or more. Theravance and its partner GlaxoSmithKline PLC (GSK) reported positive results from four Phase III tests for the treatment of chronic obstructive pulmonary disease ("COPD"). Theravance and GSK are testing LAMA/LABA, which is a mix of two molecules, in four 24-week long studies. LAMA/LABA are two molecules that dilate the bronchial passages.

Read at Seeking Alpha


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES